NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $2.29 -0.04 (-1.72%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About INmune Bio Stock (NASDAQ:INMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get INmune Bio alerts:Sign Up Key Stats Today's Range$2.29▼$2.4250-Day Range$1.62▼$2.5152-Week Range$1.09▼$2.60Volume306,664 shsAverage Volume348,114 shsMarket Capitalization$63.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions. Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer’s disease and treatment-resistant depression. The company’s second platform, INKmune, is designed to activate a patient’s natural killer cells and is being developed as an oncology immunotherapy. INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. Its clinical development activities have included studies in the United States and other regions. The company is led by Chief Executive Officer and co-founder R. J. Tesi, M.D., who has a background in medicine, oncology and biotechnology.AI Generated. May Contain Errors. Read More INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 5% of companies evaluated by MarketBeat, and ranked 874th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingINmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageINmune Bio has only been the subject of 1 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.01% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 6.26.Change versus previous monthShort interest in INmune Bio has recently increased by 3.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for INmune Bio this week, compared to 2 articles on an average week.Search Interest3 people have searched for INMB on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INMB Stock News HeadlinesINmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To BoardSeptember 15, 2026 | rttnews.comINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to BoardSeptember 14, 2026 | globenewswire.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents. | Brownstone Research (Ad)INmune Bio to Present at the H.C. Wainwright Global Investment ConferenceSeptember 9, 2026 | globenewswire.comINmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory AlignmentAugust 28, 2026 | seekingalpha.comINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory FilingsAugust 26, 2026 | globenewswire.comINmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burnAugust 7, 2026 | seekingalpha.comINmune Bio (INMB) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | finance.yahoo.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $1.56 at the beginning of the year. Since then, INMB stock has increased by 46.8% and is now trading at $2.29. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.16. Read the conference call transcript. When did INmune Bio IPO? INmune Bio (INMB) raised $20 million in an initial public offering on the week of February 4th 2019. The company issued 2,500,000 shares at a price of $8.00 per share. Who are INmune Bio's major shareholders? Top institutional shareholders of INmune Bio include BlackRock Inc. (1.17%), Ieq Capital LLC (0.30%), GSA Capital Partners LLP (0.31%) and Focus Partners Advisor Solutions LLC (0.16%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss and Scott Juda. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings8/06/2026Today9/21/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INMB's financial health is in the Green zone, according to TradeSmith. INMB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees21Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.93 million Net MarginsN/A Pretax Margin-91,866.00% Return on Equity-82.87% Return on Assets-62.23% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$50 thousand Price / Sales1,270.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book2.60Miscellaneous Outstanding Shares27,750,000Free Float21,815,000Market Cap$63.55 million OptionableOptionable Beta0.93 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:INMB) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
